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 1  
Review: Assessing the efficacy of cell transplantation for Parkinson’s 
disease: a patient-centred approach  
Abstract   
Evidence from a growing number of preclinical studies indicate that recently discovered stem 
cell lines may be translated into viable cellular therapies for people with Parkinson’s disease 
(PD). In a brief but critical review, we examine the use of primary and secondary outcome 
measures currently used to evaluate the efficacy of cellular therapies. The current practice of 
relying on a single primary outcome measure does not appear to provide the evidence required 
for demonstrating the robust, life-changing recovery anticipated with the successful 
implementation of cellular therapies. We propose a 360-degree assessment protocol, which 
includes co-primary and composite outcome measures to provide accurate and comprehensive 
evidence of treatment efficacy, from the perspectives of both the researchers and the patients.  
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Introduction 
Remarkable advances in the field of stem cell technology are anticipated to provide a supply 
of safe and standardised cell lines suitable for transplantation in people with a range of 
neurological disorders including Parkinson’s disease (PD) [1-4]. Stem cells, when shown to be 
safe and ready to be efficiently manufactured, may be used for replacing dopamine (DA) 
expressing cells in suitable patients with PD [5-7]. It is understood, however, that the successful 
translation of the new cell lines into effective treatments depends on taking into account the 
lessons learned over three decades of pre-clinical and clinical research for replacing DA 
expressing cells [8-10]. 
One of the important lessons is that confirmatory trials for evaluating the functional efficacy 
of DA expressing cells should be initiated only in the light of clear preliminary evidence of 
their safety and efficacy [11, 12]. It has been argued that the prematurely implemented double-
blind randomised control trials (RCTs) may have impeded the clinical implementation of 
cellular therapies for the treatment of PD [12]. A multi-centre project (TRANSEURO) is 
currently being completed to demonstrate the effect of key factors, such as patient selection, 
tissue composition, surgical techniques and trial designs for transplanting DA expressing foetal 
cells [6, 9].  
Ideally, pre-clinical and clinical evidence should be integrated into a coherent treatment 
protocol for guiding further advances in stem cell research leading up to the evidence-based 
implementation of cellular therapies. To quote Dunnett and Rosser [13], “Only once a fully 
reliable and effective standardised treatment protocol is determined is it appropriate to seek 
validation in a randomised control trial” (p.85) 
In order to develop an effective treatment protocol, it is essential to explore the psychosocial 
processes which enable patients to achieve optimal recovery following the transplantation of 
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cells [12, 13]. It has been argued previously that a multi-disciplinary patient-centred approach 
is most suitable for ensuring the best possible health outcomes for people with chronic, 
disabling conditions such as PD [14]. Therefore, we propose a patient-centred approach to data 
collection for identifying the anticipated structural and concomitant functional improvements 
in people undergoing stem cell transplantation. 
The aims of this article are to review the limitations of current strategies for producing evidence 
to demonstrate the efficacy of cellular therapies and to propose a patient-centred, 
biopsychosocial approach to evaluating the preliminary and confirmatory efficacy of cell-based 
therapies. 
Approaches to Evaluation of Treatment Efficacy 
It is now accepted that the transplantation of DA expressing stem cells will not provide a cure 
for Parkinson’s disease [9-11]. Rather, if successful, cell replacement therapies are expected to 
reverse the progressive loss of DA which follows the degeneration of the nigrostriatal system 
and to improve motor and psychosocial functioning [10, 13, 15]. This section provides a brief 
overview of how measurement tools have been used by researchers to evaluate the preliminary 
and confirmatory efficacy of cell or gene-based interventions for PD.  
Protocols for selecting measurement tools  
Owing to the progressive damage to multiple neural systems and the fact that the presentation 
and severity of the biological impairments and psychosocial dysfunctions vary markedly across 
people with PD [16], there has been a determined effort to select and organise outcome 
measures into coherent assessment batteries.  
A protocol for selecting standardised assessment tools, referred to as the Core Assessment 
Program for Intracerebral Transplantation (CAPIT) was devised to guide research and 
evaluation of intracerebral neurotransplantation for PD. The CAPIT protocol provided a 
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comprehensive list of outcome measures applicable to collect data on key dimensions of PD 
[17]. The CAPIT protocol was revised to create the Core Assessment Program for Surgical 
Intervention Therapies (CAPSIT-PD) for the evaluation of the safety of different types of 
surgical interventions for PD. Further, in recognition of growing evidence for non-motor 
impairments, the CAPSIT-PD also included standardised tests of memory, cognition and 
emotional states in people with PD following surgical interventions [18]. Although the CAPIT 
protocol seems to be no longer in general use, the idea of the importance of a standardised, 
multi-source assessment tool remains relevant to our present discussion.  
Primary and secondary outcome measures 
There are numerous standardised measurement tools available and applicable for clinical 
evaluation and research. The United Parkinson’s Disease Rating Scale (UPDRS) is an example 
of a comprehensive tool, which has been used in numerous research studies to track the 
progression of PD. The UPDRS consists of four subscales to assess functional changes 
including cognition and mood, activities of daily living (ADL), motor symptoms UPDRS 
motor and the complications of therapy [19] The UPDRS is typically administered under two 
conditions; patient without medications (UPDRS ‘off’) or while the patient is using 
medications (UPDRS ‘on’). The UPDRS was revised by the Movement Disorder Society to 
produce the MDS-UPDRS [20]; however, most of the available evidence for the efficacy is 
based on the original version of the UPDRS.  
In order to confirm the efficacy of an intervention which involves neurosurgical procedures, 
researchers follow a general strategy as described, for example in the ‘CONSORT’ statement 
[21]. Briefly, having designed a randomised controlled trial (RCT) researchers nominate a 
primary outcome measure and specify an endpoint for completing the trial. The efficacy of the 
intervention is demonstrated by statistically and clinically significant differences on the 
primary outcome between the treatment and control groups. The primary outcome measures 
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are also important to conduct power analyses and are relied on to conduct meta-analyses to 
synthesize the results of related trials [9, 12]. 
A host of secondary outcomes are also used to evaluate changes on constructs relevant to 
cellular therapies for PD, such as cognitive and emotional changes. However, research groups 
tend to differ on how they report the data on secondary outcome measures and the degree of 
importance they attribute to the secondary outcomes [9, 22, 23]. There appear to be no explicit 
rules for deciding how primary and secondary outcomes should be selected to determine 
treatment efficacy. Considering the decisive importance of primary outcome measures, there 
is a need for evidence-based discussion for identifying the criteria required for designating the 
available assessment tools into primary and secondary categories.  
A critical look at using data generated by current assessment tools 
It is understood that there is a need for an outcome measure which clearly indicates a long-
term, life changing recovery for the therapeutic benefits of the cell transplantation program 
[24, 25]. In this section, we will examine if a single primary outcome measure is adequate for 
the task of establishing the efficacy of cellular therapies.  
Selection of the primary outcome measure  
Research groups developing and evaluating surgical interventions differ in their selection of 
primary outcome measures for assessing the outcomes of surgical treatments for PD. For 
example, groups evaluating the efficacy of Deep Brain Stimulation (DBS) nominated a variety 
of primary outcomes, such as, time spent in the ‘on’ state without troubling dyskinesia [26] or 
the “total score on PDQ39” [27]. In contrast, groups evaluating cellular therapies have 
generally selected the UPDRS (motor, off) as the primary outcome for evaluating efficacy [23].   
In some studies, the degree to which transplanted dopamine cells survive, as measured by F-
fluorodopa PET scans, correlates positively with symptomatic recovery as measured by 
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UPDRS (motor) in open-label studies of fetal cell transplantation [28]. However, in other 
studies where significant increase in DA activity were found there were no significant benefits 
on UPDRS outcomes in the transplanted groups [29]. Further, statistically significant 
improvements on UPDRS (motor) do not consistently correlate with significant improvements 
on secondary outcomes, such as Quality of Life (PDQ39) outcomes [30]. The uncertainty in 
confidently predicting correlations among improvement on the primary and secondary 
measures of efficacy indicates the need to critically evaluate the construct validity of current 
assessment tools. 
Another problem with primary outcome measures is the uncertainty with deciding on the 
magnitude of improvement which indicates a clinically significant effect size. For example, Ko 
and colleagues [31] nominated a threshold of 2 point (approximately 5%) improvement on 
UPDRS (motor) as their criterion for identifying placebo responders. In contrast, LeWitt and 
colleagues [30] selected a minimal 9-point difference which has been previously identified  as 
an indicator of strong efficacy [32]. Further, a meta-analysis relied on a 33% or greater 
improvement on UPDRS (motor) to indicate recovery [12]. The rationale for choosing this 
threshold was that this effect size has been  used as a criterion for identifying L-DOPA related 
medication benefits [17]. Barker and colleagues, anticipated a 50% improvement on UPDRS 
(motor) improvement in the group receiving DA expressing cells in an ongoing 
(TRANSEURO) trial [9]. Unquestionably, this would be a decisive effect size, comparable to 
the efficacy of Deep Brain Stimulation (DBS) which has been adopted for clinical treatment 
[26, 27]. The question, from a person-centred approach to data collection, is if motor 
improvements by themselves constitute adequate evidence for the clinical efficacy. 
Perspectives of the cell recipients 
While significant improvements, as exemplified by UPDRS (motor, off) are important 
indicators of efficacy from the researchers’ perspective, there is the question of whether the 
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patients with advanced PD also see this as a meaningful, life changing recovery. There is 
evidence that the post-treatment changes in motor symptoms before taking medications are not 
necessarily the primary concerns of people with advanced PD [33]. 
The issue here is that standardised tests, such as UPDRS (ADL) or PDQ39 to assess patients’ 
experiences on predetermined questions, thereby confining possible responses to quantifiable 
characteristics of the patients on operationally defined factors. There may be additional 
information that participants need to communicate regarding their experiences of the recovery 
process and the perceived benefits and limitations of the treatment. It has been suggested that 
additional evidence, based on the rigorous application of qualitative methods, would provide 
the detailed information necessary for understanding recovery from the participant’s 
perspectives [12, 34]. Qualitative research has a long history in providing evidence essential to 
understand the experiences of people with PD [34]. We propose that this method should be 
also an integral component of conducting research and evaluation in the field of reconstructive 
therapies using stem cells [6, 34, 35].  
This brief critique questions the validity of relying on a single primary outcome measure, such 
as UPDRS (motor off) as the evidence for a meaningful, life changing measure of treatment 
efficacy. Unquestionably, improvement of motor symptoms are necessary components of the 
evidence, but are not sufficient by themselves to confirm the efficacy of cell transplantation.  
Co-primary endpoints for the quantitative assessment of recovery 
Researchers and regulators previously addressed issues associated with evaluating treatments 
for complex disorders where multiple endpoints are required for establishing efficacy [36-38]. 
The use of co-primary endpoints and composite outcome measures were recommended for 
evaluating the results of trials where two or more outcomes were considered to be essential 
components of the evidence for efficacy [36]. In the light of the problems associated with 
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relying on a single primary outcome, we propose an alternative, multi-source assessment 
protocol, based on the biopsychosocial model. Application of this approach to collecting data 
for demonstrating the efficacy of cellular therapies requires evidence on the essential 
dimensions of the recovery process.   
The following five dimensions of recovery for cellular therapies are suggested, based on the 
biopsychosocial categories recommended by McGinley and Danoudis for organizing currently 
used assessment tools for PD [39].  
(I) Reversal of neuropathology: For cell replacement therapies, it is essential to provide 
evidence for significant levels of cell survival and significant increases in DA 
activity [28, 29]. Measurements tools, which produce data for changes in DA 
functioning, such as F-Flurodopa PET scans, are absolutely necessary for 
evaluating the efficacy of DA replacement therapies.  
(II) Improved response to medications: Although medications such as L-DOPA are 
effective in the earlier stages of PD, with the inexorable degeneration of the 
nigrostriatal system there is a gradual loss of their efficacy. Quantity of medication 
use is recorded by treating physicians and changes are usually reported as L-dopa 
equivalents. Adverse side effects, such as dyskinesias and also the time intervals 
during which drugs are not effectively controlling motor symptoms are also 
recorded by the research participants, in diaries designed for this purpose. If the 
treatment is effective then the increased DA turnover should be correlated with an 
improved response to medications.  
(III) Symptomatic changes in motor functioning: Improvement on motor functioning, as 
for example assessed by UPDRS (motor) is essential for demonstrating the efficacy 
of stem cell therapies. Symptomatic improvements should be correlated with 
positive outcomes on (I) and (II).  
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(IV) Activity levels: We suggest that the cell transplantation cannot be judged as effective 
without significant improvements on ADL outcomes. The ADL subscale of the 
UPDRS is used to assess the subjective reports of people with PD regarding their 
ability to perform basic activities, indicating toileting, preparing meals or house 
maintenance.  
(V) Changes in social participation and quality of life: As with activities of daily living, 
meaningful improvements in quality of daily life are necessary attributes of a 
clinically effective treatment of PD. The Parkinson’s Disease Questionnaire 
(PDQ39) is a standardised questionnaire, which has been relied on as an overall 
indicator of the quality of life (QoL) [40]. All the above factors (V) should be 
correlated for indicating a clinically meaningful recovery, and thereby confirming 
the efficacy of stem-cell transplantation. 
There are many other measurement tools currently available to assess changes in the progress 
of PD; we only presented a very limited sample in this brief overview. There are ongoing 
technological changes which may lead to new and more accurate assessment tools which could 
lead to improved assessments of efficacy [41]. 
The key point here is that the five domains of recovery described above are hypothesized to 
represent the interacting components of an integrated system representing the recovery process 
following the grafting of cells. By postulating an integrated system, we propose that the 
evidence for improvements in each of the numerical components is essential to represent and 
understand the mode of action of the transplanted cells. When the specific tools are selected, it 
may be possible to synthesize 5 scores into a ‘global’ quantitative indicator measure, as 
previously adopted by Kieburtz and colleagues [42].  
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Composite Results  
<table 1> 
In addition to the five quantitative domains of the recovery process described above, a patient-
centred approach also requires detailed evidence from the perspectives of the participants. The 
original idea for the proposed 360-degree assessment protocol comes from the discipline of 
organisational psychology (e.g. [43, 44]). In this discipline, multi-source assessment protocols 
(such as self-reported, supervisor/peer reported) have been used for the evaluation of 
organisational factors such as performance or job-satisfaction. Although the evaluation of 
performance in organizational settings is very different to that of conducting cellular therapies, 
we suggest that the logic underlying the two multi-perspective assessments is arguably 
identical.  
As shown in Figure 1, the proposed 360-degree multi-source assessment entails two orthogonal 
factors; the source of the data (subjective / objective) and the form of the data (numerical / 
narrative). The model postulates that data collected from the four different domains (A, B, C 
and D) integrated into a combined response (CR). As discussed below, CR provides the 
evidence for a meaningful, life-changing recovery following cell transplantation. 
 
<Figure 1: Model for a 360-degree assessment of recovery in PD> 
The components of the multi-source model include existing quantitative measures (dimensions 
A and B) as those listed in CAPSIT-PD. It is understood that these remain essential for the 
assessment of changes of variations representing treatment efficacy. 
 ‘A’ represents numerical, self-reported data generated by participants using 
standardised questionnaires such as data from the PDQ39 or UPDRS (ADL).  
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  ‘B’ represents numerical data assessed by observers or clinicians using 
instrumentation such as PET-scans or standardised assessment scales, as for instance 
UPDRS (motor). 
In addition to the numerical measures, the multi-source protocol explicitly incorporates two 
qualitative dimensions (C and D). The narratives are included in the assessment protocol to 
enable understanding the therapeutic outcomes from the perspectives of the people with PD, 
as well as the health professionals who are working with the participants following the 
interventions. The themes emerging from these narratives provide detailed information about 
the experiences of the participants and the social context in which recovery takes place 
following cell transplantation.  
  ‘C’ represents narrative data recorded by observers or clinicians describing changes 
in the participants’ symptoms and level of activity and social participation.  
  ‘D’ represents narrative data reported by people with PD describing their personal 
experiences and the perceived impacts of the intervention for overcoming specific 
aspects of activity limitations and levels of social participation associated with PD.  
Data collection for C & D dimensions do not require standardised measurement tools but rather 
face-to-face interactions including semi-structured and in-depth interviews, and the 
observation of and interactions with participants over a period of time in their physical 
environments and social settings. 
Brief case studies (C) written of each patient by researchers provides valuable insights into the 
progress of the patients. An example of how this has been implemented can be seen in the 
reports of Swedish researchers [7] who provided brief summary for the progress of each of 
their participants in a longitudinal study of the benefits of cell transplantation for PD. For 
example, quoting the report on Patient 7: “…This patient is now running his own business on 
a full-time basis (he previously worked part-time) and has been able to take up car driving 
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again, which was impossible before surgery” [7].  This information by itself is not decisive, as 
it is coloured by the biases, expectations and values of the expert observers. However, when 
triangulated with relevant quantitative sources of evidence, the narrative data contributes 
valuable information for enabling a holistic overview of the recovery process [12].  
Component ‘D’ describes the experiences and consequences of cellular therapies from the 
participants’ perspectives. It is essential to establish that objectively measured improvements 
are consistent with the expectations and values of the people with PD. This evidence is best 
collected by interacting with research participants in the context of rigorously applied 
qualitative methods [34, 45]. Qualitative data are analysed to produce the themes, which enable 
researchers to interpret empathically the experiences and the reasons for the actions of people 
with PD undergoing cellular therapies.  
The concept of themes is illustrated by a study by O’Brian and colleagues [46] who conducted 
semi-structured interviews to collect data to explore the personal meanings of participating in 
exercise program for people with PD. Analysis of the narrative data generated four major 
themes: adapting to pain and loss, the influence of others, making sense of the exercise 
experience and hope for a more active future. These themes provided the information 
applicable to understanding the barriers and facilitators which influenced the participants’ 
successful completion of the exercise programs.  
A study by Fisher and colleagues [47] demonstrates how data from quantitative and qualitative 
sources can be combined to evaluate the acceptability of body-worn remote movement sensors. 
The experiences of participants with PD were evaluated by three different methods of data 
collection; a qualitative ‘free text response’, a structured quantitative questionnaire and the 
recording of estimated ‘non-wear time’. The synthesis of data from the three sources were 
triangulated to provide ecologically valid evidence applicable to facilitating the wearing of the 
sensors by the research participants with PD in their everyday environment.  
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As stated earlier, the composite results (CR) refer to the proposed synthesis of the results on 
each measure from the dimensions A, B, C and D. The scores are used to determine the overall 
positive response of each participant to the cellular therapies. CR is not a specific, weighted 
statistic but rather the demonstration of satisfactory outcomes on each dimension, as reported 
from the perspectives of the researchers and the participants. Ideally, a ‘satisfactory score is 
represented by, (1) improvment on each of the five quantitative measurements in A and B also 
and (2) the report of perceived improvements in activity levels and the quality of everyday life 
(C and D).  
Application to stem cell research 
The translation of stem cell research into viable treatments begins with extensive and detailed 
pre-clinical experiments.  The aim of pre-clinical research is to demonstrate, the mode of 
actions of the cells in animal models and to estimate the probable safety and efficacy of the 
cells in human participants [7, 48].  
Phase 1, preliminary safety and feasibility studies with human participants aim to identify 
adverse events associated with the transplantation of the cells to determine if the dose levels 
are adequate and ultimately, to enable the researchers to decide if further efforts to develop the 
stem cell line is justified. In general, preliminary studies involve small sample sizes and open-
label designs, where a single primary outcome measure of efficacy such as UPDRS motor, 
appears sufficient for further trials [49]. 
Phase 2, preliminary efficacy studies [49] aim to provide detailed evidence for the safety and 
clinical benefits of stem cell transplantation for PD. As stated by [49] this stage of the research 
program requires a primary outcome measure which “…must show an improvement that is 
clinically meaningful to a patient so that the risk of a neurosurgical procedure is reasonably 
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balanced by the potential clinical benefits and the value of the generalizable knowledge.” 
(p.647) 
We suggest that the 360-degree assessment protocol is well suited to the task of assessing the 
preliminary efficacy of DA expressing stem cells. Of course, the results of additional secondary 
outcome measures and most importantly, the occurrence of adverse events must be also 
included in the data. As discussed earlier, the preliminary efficacy measure should clearly 
indicate significant effect sizes at the endpoint of open-label studies before confirmatory 
studies are initiated.  
Phase 3, confirmatory studies rely on RCT designs where a sample of participants with PD are 
randomly assigned to either stem cell treated, active group(s) or to the control groups(s) [49]. 
Statistically significant and clinically meaningful difference in favour of the transplanted 
groups at the designated endpoint is the accepted criterion for treatment efficacy. Significant 
differences in favour of the transplanted group on the five co-primary outcomes, if consistent 
with qualitative reports, would provide convincing evidence for the efficacy of stem cell 
transplantation.  
Further, the 360-degree, person-centered evaluation enables the accurate identification of 
individual research participants who have definitely improved by the endpoint of the trial. The 
combined response (CR) may be used to indicates the proportion of people in the control and 
stem cell treated groups who have convincingly improved over a given period of time. The 
confirmation of the efficacy of stem cell lines would be decided by the proportion of 
participants in the control and treated groups identified as achieving a satisfactory composite 
result. The results of the RCT would be analysed using inferential statistics for nominal data, 
such as odds ratios, to demonstrate the statistical and practical significance of the efficacy of 
the transplantation of stem cells.  
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Summary 
A compelling lesson learned from previous research is that confirmatory trials of the efficacy 
of new stem cell lines for the treatment of PD should be initiated only after an evidence-based, 
conceptually sound treatment protocol is constructed. From a patient-centered perspective, the 
current practice of relying on a single primary outcome measure does not provide the evidence 
required to demonstrate the life-changing recovery which would confirm the efficacy of 
transplanting stem cells in people with PD. 
We proposed an alternative evaluation strategy, which uses five co-primary outcome measures 
(Fig.1) to demonstrate that the transplantation of the cells increases the expression of DA, 
improves response to medications, ameliorates motor symptoms, and enhances activity levels 
and social participation in patients. Further, the 360-degree protocol explicitly takes into 
account the participant’s experiences as a necessary component of the evidence for determining 
efficacy. The proportion of people with PD in the transplanted group may be compared to the 
controls to determine the efficacy of stem cell therapies in comparison to control treatment. 
We recognize that this is a very preliminary presentation of the proposed assessment protocol. 
Many questions need too be answered before we can decide if the 360-degree protocol 
improves the accuracy of the evidence for evaluating the efficacy of stem cell therapies for PD. 
If further evidence supports the validity of this assessment protocol, it may be perhaps also be 
considered for evaluating other novel interventions for the treatment of PD.  
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Figure 1: Model for a 360-degree assessment of functioning in PD 
 
 
A: represents numerical, self-reported data generated by participants using standardised 
questionnaires. 
B: represents numerical data assessed by observers or clinicians using standardised 
measurement tools. 
C: represents narrative data recorded by observers or clinicians.  
D: represents narrative data reported by people with PD – combined results.  
CR: represents the composite or combined response which ideally includes improvement on 
all the four dimensions.   
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Dimensions of Recovery following  
Cell Transplantation 
Examples of relevant 
Measurement Tools  
I. Substantial number of transplanted cells survive 
and express DA, 
18F-flurodopa PET scan 
II. The participants experienced an enhanced response 
to medications,  
Reduction in levodopa 
equivalent 
III. Improvement in motor symptoms, UPDRS (motor) 
IV. Participants experienced improved levels of 
activity,  
UPDRS (ADL) 
V. Clear evidence for enhanced social participation 
and quality of life. 
PDQ 39 
Table 1. Dimensions of recovery and examples of relevant standardised outcome 
measures. 
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